FATE
NASDAQFate Therapeutics Inc.
Website
News25/Ratings12
News · 26 weeks34+50%
2025-10-262026-04-19
Mix1690d
- Other12(75%)
- SEC Filings2(13%)
- Insider2(13%)
Latest news
25 items- INSIDERAmendment: SEC Form 4 filed by Director Redmile Group, Llc4/A - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Redmile Group, Llc4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Fate Therapeutics Inc.SCHEDULE 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)
- PRFate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual MeetingSAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that preclinical data from the Company's next-generation, off-the-shelf CAR T-cell product candidate, FT839, will be featured at the American Association for Cancer Research Annual Meeting, being held in San Diego, CA on April 17-22, 2026. The Company has been selected to participate in a poster presentation featuring preclinical data from FT839, its next generation, 13-point edit
- PRFate Therapeutics to Participate in Upcoming Second Quarter 2026 ConferencesSAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in five upcoming investor conferences in the second quarter of 2026. 25th Annual Needham Virtual Healthcare Conference Location: Virtual Date: April 14th Bank of America Healthcare Conference 2026 Location: Encore at the Wynn - Las Vegas, NV Date: May 13th H.C. Wainwright 4th Annual BioConnect Investor Conference Location: Nasdaq
- PRFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering in
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Fate Therapeutics Inc.SCHEDULE 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
- PRFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 2, 2026, the Company granted restricted stock units (RSUs) representing 50,700 shares of its common stock to three newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees ente
- PRFate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare ConferenceSAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat and host investor meetings at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida. Management will participate in a fireside chat at 9:20 AM ET on Monday, March 9. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors section of the Compan
- PRCell Therapies Moving From Lab to Factory Floor, and the Stocks Behind ThemIssued on behalf of Avaí Bio, Inc.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical breakthroughs and manufacturing milestones reshaping regenerative medicine[1]. CAR T-cell therapy alone is valued at nearly $7 billion this year, expanding at an 18% compound annual growth rate as off-the-shelf platforms eliminate the logistical barriers that once limited patient access[2]. Among the companies advancing next-generation cell-based treatments are Avaí Bio (OTCQB:AVAI), FibroBiologics (NASDAQ:FBLG), Fate Therapeutics (NASDAQ:FATE), Mesoblast (NASDAQ:MESO), and Longeve
- SECSEC Form 10-K filed by Fate Therapeutics Inc.10-K - FATE THERAPEUTICS INC (0001434316) (Filer)
- SECFate Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
- PRFate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesOutpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first idiopathic inflammatory myopathy patient treated with FT819; First systemic sclerosis patient reaching 3-month evaluation timepoint shows meaningful disease improvement using less-intensive conditioning chemotherapy FT819 Phase 1 enrollment expanded across 16 clinical sites in the U.S., U.K. and EU, with 15 systemic lupus erythematosus patients enrolled to date, supported by increased interest in FT819 safety, efficacy and on-demand accessibility profile Colorectal cancer
- PRIPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightNew York, USA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and commercial analysis. DelveInsight's 'IPSC-derived NK Cells Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for IPSC-derived NK cells across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitiv
- PRFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 1, 2026, the Company granted to one newly-hired non-executive employee (i) non-qualified stock options to purchase a total of 120,000 shares of the Company's common stock at an exercise price per share of $1.19, which was the closing price per share of the Company's common stock as reported by NASDAQ on January 30, 2026, and (ii) restricted stock units (RSUs) repres
- PRBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease MarketsIssued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Jan. 26, 2026 /PRNewswire/ -- The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for high-tech cures for long-term illness. A major FDA move at the beginning of the year[2] is now making it much easier to build these advanced platforms, clearing a path for companies that can treat diseases internally without the harsh side effects of traditional drugs. This regulatory shift positions Avant Technologies, Inc. (OTCQB:AVAI), MannKind (NASAQ: MNKD), Vertex Pharmaceuticals (NASDAQ:VRTX), Fate Therapeutics (NASDAQ:FAT
- PRBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease MarketsVANCOUVER, British Columbia, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for high-tech cures for long-term illness. A major FDA move at the beginning of the year[2] is now making it much easier to build these advanced platforms, clearing a path for companies that can treat diseases internally without the harsh side effects of traditional drugs. This regulatory shift positions Avant Technologies, Inc. (OTCQB:AVAI), MannKind (NASDAQ:MNKD), Vertex Pharmaceuticals (NASDAQ:VRTX), Fate Therapeutics (NASDAQ:FATE), and Ardelyx (NASDA
- INSIDEROfficer Tahl Cindy was granted 100,000 shares, increasing direct ownership by 26% to 487,081 units (SEC Form 4)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERChief Financial Officer Adawi Kamal was granted 25,000 shares, increasing direct ownership by 33% to 100,000 units (SEC Form 4)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERPresident and CEO Valamehr Bahram was granted 335,000 shares, increasing direct ownership by 102% to 664,708 units (SEC Form 4)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDEROfficer Tahl Cindy sold $11,275 worth of shares (10,589 units at $1.06), decreasing direct ownership by 3% to 387,081 units (SEC Form 4)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERPresident and CEO Valamehr Bahram sold $5,557 worth of shares (5,190 units at $1.07), decreasing direct ownership by 2% to 329,708 units (SEC Form 4)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- PRFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on January 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 48,000 shares of the Company's common stock at an exercise price per share of $0.98, which was the closing price per share of the Company's common stock as reported by NASDAQ on December 31, 2025, and (ii) restricted stock units (RSUs) represe
- SECSEC Form 144 filed by Fate Therapeutics Inc.144 - FATE THERAPEUTICS INC (0001434316) (Subject)
- PRFate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell ProgramsFT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated First ex-U.S. SLE patient treated with FT819 expands enrollment capacity and supports unique ability of FT819 for broad, on-demand patient accessibility Preclinical studies show FT836 chimeric antigen receptor (CAR) T cells uniquely targeting stress antigens MICA/B, combined with daratumumab, provide a comprehensive approach to treatment of multiple myeloma FT839 CAR T cells demonstrate the unique ability to treat a wide range of B-cell malignancies and autoimmune diseases through dual